HARNEET KAUR: Open Payments
NPI 1346705845 · TOMBALL, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$707 in 30 payments from 12 companies in 2025. Trend: 2023 $1,017 · 2024 $944 · 2025 $707
Food & beverage: $707
| Company | Payments | Amount |
|---|---|---|
| Galderma Laboratories, L.P. | 3 | $231 |
| Lilly USA, LLC | 9 | $124 |
| GlaxoSmithKline, LLC. | 5 | $80 |
| Corcept Therapeutics | 2 | $48 |
| PFIZER INC. | 2 | $45 |
| Novo Nordisk Inc | 2 | $38 |
| Madrigal Pharmaceuticals | 1 | $32 |
| AstraZeneca Pharmaceuticals LP | 2 | $30 |
| Boston Scientific Corporation | 1 | $28 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $21 |
Products named: MOUNJARO, DYSPORT, TRELEGY ELLIPTA, Korlym, PREVNAR 20, REZDIFFRA, General - Therapies, JOURNAVX.
Industry payments across TX — which companies pay providers there.
